Earlier Diagnosis of Alzheimer’s Disease Attained with New PET Tracers
By MedImaging International staff writers Posted on 11 Mar 2014 |
Image: PET scans showing the differences between a normal older adult\'s brain and the brain of an older adult afflicted with Alzheimer\'s disease (Photo courtesy of the NIH).
New nuclear imaging techniques are helping to diagnose Alzheimer’s disease (AD) much earlier than ever before. Recently developed tracers, used with positron emission tomography (PET) imaging, make beta-amyloid in the brain visible. This part of a protein, which is a key causal factor of Alzheimer’s, can now be identified way before the onset of the disease’s signs.
“This helps doctors to confirm their diagnosis and to plan the individually appropriate treatment strategy right from the start. Also, it will allow [us] to apply future medications, which are currently being developed, in time,” said Prof. Swen Hesse, a specialist from the European Association of Nuclear Medicine (EANM; Vienna, Austria).
The earlier treatment begins for AD, the higher its effectiveness. The fact that newer and more lasting therapies might become available soon increases the significance of early diagnosis. The target of the PET scan is beta-amyloid, which is the chief component of plaques that harm the brain’s neurons and are one of the hallmarks of ADs. Three different tracers (radioactively labelled substances the patient is injected with) have been recently developed, which make these plaques visible on the computer screen. One of the compounds (florbetapir F-18) has already been approved by the healthcare authorities of the European Union and the United States alike, whereas the two other ones (flutemetamol F-18 and florbetaben F-18) are expected to be approved by both authorities soon. With the aid of these tracers, the probability that AD can be detected up to 15 years before the onset of severe mental impairment.
However, while a negative PET scan—one that shows little or no beta-amyloid accumulation in the brain—excludes AD as the cause of the patient’s disease, this does not quite perform the same because other forms of dementia such as dementia with Lewy bodies (DLB) can also have positive scans, and a positive scan does not inevitably mean clinical dementia. Ongoing studies will reveal whether the use of radioactive amyloid tracers and PET imaging can forecast the individual risk of future conversion to AD dementia and whether they are suited to assess how patients respond to treatment. The nuclear imaging techniques, for now, are not a replacement but a valuable addition to established diagnostic tools.
“Amyloid imaging allows doctors to determine right from the start and with high accuracy whether, in patients with mild symptoms, Alzheimer’s can be excluded, so that some other kind of dementia or another condition has to be taken into account,” remarked Prof. Hesse. “The effectiveness of these substances was established in excellent clinical studies that showed their accuracy in detecting beta-amyloid in the brain according to histopathological results.”
Amyloid imaging, according to the EANM, will further treatment approaches by helping to select study participants into clinical trials, which may lead to disease-modifying drugs. Such tracers are also prone to new combinations of PET with magnetic resonance imaging (MRI) as stand-alone examinations, being, in fact, two devices in one. This will further reduce scanning time and increase patient’s comfort, according to the scientists.
Related Links:
European Association of Nuclear Medicine
“This helps doctors to confirm their diagnosis and to plan the individually appropriate treatment strategy right from the start. Also, it will allow [us] to apply future medications, which are currently being developed, in time,” said Prof. Swen Hesse, a specialist from the European Association of Nuclear Medicine (EANM; Vienna, Austria).
The earlier treatment begins for AD, the higher its effectiveness. The fact that newer and more lasting therapies might become available soon increases the significance of early diagnosis. The target of the PET scan is beta-amyloid, which is the chief component of plaques that harm the brain’s neurons and are one of the hallmarks of ADs. Three different tracers (radioactively labelled substances the patient is injected with) have been recently developed, which make these plaques visible on the computer screen. One of the compounds (florbetapir F-18) has already been approved by the healthcare authorities of the European Union and the United States alike, whereas the two other ones (flutemetamol F-18 and florbetaben F-18) are expected to be approved by both authorities soon. With the aid of these tracers, the probability that AD can be detected up to 15 years before the onset of severe mental impairment.
However, while a negative PET scan—one that shows little or no beta-amyloid accumulation in the brain—excludes AD as the cause of the patient’s disease, this does not quite perform the same because other forms of dementia such as dementia with Lewy bodies (DLB) can also have positive scans, and a positive scan does not inevitably mean clinical dementia. Ongoing studies will reveal whether the use of radioactive amyloid tracers and PET imaging can forecast the individual risk of future conversion to AD dementia and whether they are suited to assess how patients respond to treatment. The nuclear imaging techniques, for now, are not a replacement but a valuable addition to established diagnostic tools.
“Amyloid imaging allows doctors to determine right from the start and with high accuracy whether, in patients with mild symptoms, Alzheimer’s can be excluded, so that some other kind of dementia or another condition has to be taken into account,” remarked Prof. Hesse. “The effectiveness of these substances was established in excellent clinical studies that showed their accuracy in detecting beta-amyloid in the brain according to histopathological results.”
Amyloid imaging, according to the EANM, will further treatment approaches by helping to select study participants into clinical trials, which may lead to disease-modifying drugs. Such tracers are also prone to new combinations of PET with magnetic resonance imaging (MRI) as stand-alone examinations, being, in fact, two devices in one. This will further reduce scanning time and increase patient’s comfort, according to the scientists.
Related Links:
European Association of Nuclear Medicine
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure